Welcome to Pathognomia Podcast 🎙️ — where we decode complex guidelines into practical bedside wisdom.

In this episode, we take a deep dive into the GINA 2025 Asthma Guidelines, exploring what every clinician, resident, and student must know. From the paradigm-shifting “no SABA-only” approach to practical stepwise therapy, this episode breaks down the science, evidence, and real-world implications of modern asthma management.

We’ll cover:

Why SABA monotherapy is no longer recommended 🚫

The role of ICS-formoterol as both reliever and controller

Updated stepwise management across mild to severe asthma

Special situations: pediatrics, elderly, comorbidities, and pregnancy

Key trial evidence (SYGMA, Novel START, PRACTICAL) shaping these changes.

How to implement GINA 2025 in OPD, ER, and ICU practice

Whether you’re preparing for exams, polishing your clinical acumen, or simply keeping up-to-date with global respiratory standards — this episode will give you clarity, confidence, and clinically actionable knowledge.

Disclaimer:

This podcast is AI-generated educational content, curated from authentic, evidence-based sources including GINA 2025 guidelines and landmark clinical trials. It is intended for healthcare professionals and medical students. While every effort is made to ensure accuracy, listeners are advised to cross-check with official guidelines and exercise clinical judgment before applying this information. This is not a substitute for professional medical advice.

In this deep-dive episode of Pathognomia, we look beyond the smoker’s cough and uncover the evolving story of Chronic Obstructive Pulmonary Disease (COPD) through the lens of the 2025 GOLD Guidelines. COPD is more than airflow limitation — it’s a systemic condition with diverse presentations, comorbidities, and treatment challenges. The latest GOLD update emphasizes personalized care, shifting the focus from rigid staging to a dynamic, patient-centered model.

🔹 What we cover:

• The updated 2025 definition of COPD and its early pathological changes

• Refined assessment tools for symptoms and exacerbation risk

• Non-pharmacological care: smoking cessation, pulmonary rehab, vaccination, oxygen, and digital health

• Stepwise pharmacological updates: LABA, LAMA, ICS, triple therapy, and where biologics fit in

• Exacerbation management: steroids, antibiotics, and ventilatory strategies

• GOLD’s stance on overlap syndromes (COPD-asthma) vs GINA perspectives

• Comorbidities — why cardiovascular disease, osteoporosis, and depression are central to COPD care

• Key differences between GOLD 2023/24 and GOLD 2025 that matter at the bedside.

🎧 Why listen?

Pathognomia doesn’t just summarize guidelines — it translates them into reasoning and practice. Every recommendation is unpacked in a way that residents, intensivists, and exam-going postgraduates can apply in real clinical settings.

🔑 Episode Pearl:

“The 2025 GOLD Guidelines transform COPD care into a personalized journey — balancing inhalers, comorbidities, and lifestyle interventions. This isn’t just about treating symptoms; it’s about reshaping outcomes and improving lives.”

⚠️ Disclaimer:

This episode was generated using AI narration based on authentic, evidence-based medical notes. It is intended for educational purposes only and should not substitute professional medical judgment. For patient care, always rely on official guidelines and individualized clinical assessment.